FOXO4-DRI
A peptide designed to selectively kill 'zombie cells' — old, damaged cells that have stopped dividing but stay alive and pump out inflammatory signals. They accumulate with age and contribute to chronic inflammation. This peptide breaks the mechanism that keeps them alive, allowing them to die off. In aged mice it showed rejuvenating effects, but it's still highly experimental for humans.
Dosage
Research only — no established human dosing
Dosages shown are for research reference only. Always consult a qualified healthcare provider.
Half-Life
Extended (hours to days; D-amino acid configuration resists protease degradation)
Half-Life Calculator →Administration
Subcutaneous injection (research)
Shop Research-Grade Peptides
99%+ purity · US-based · third-party lab tested
Getting Started — Here's What You'll Need
Effects
Senolytic Action
Selectively kills senescent 'zombie cells' while sparing healthy cells.
Rejuvenation
Restored physical fitness, fur density, and renal function in aged mice.
Mechanism of Action
FOXO4-DRI is a D-retro-inverso (DRI) peptide — a peptide composed entirely of D-amino acids (mirror image of natural L-amino acids) assembled in reverse sequence order. This DRI modification makes the peptide virtually invisible to cellular proteases (which have evolved to cleave L-amino acid peptide bonds), dramatically extending its biological half-life while preserving the spatial orientation of key amino acid side chains needed for target interaction.
The target is the FOXO4-p53 protein-protein interaction that keeps senescent cells alive. Cellular senescence is a state of permanent cell cycle arrest triggered by DNA damage, oncogene activation, or telomere shortening. Senescent cells would normally undergo p53-mediated apoptosis (programmed cell death), but they evade this fate through a survival mechanism: the transcription factor FOXO4 is selectively upregulated in senescent cells and physically binds to p53, sequestering it in PML (promyelocytic leukemia) nuclear bodies. This binding prevents p53 from activating its pro-apoptotic transcriptional program (PUMA, BAX, NOXA), keeping the damaged cell alive.
FOXO4-DRI competitively disrupts this interaction by mimicking the FOXO4 binding interface for p53 but without the nuclear body-localizing function. When FOXO4-DRI competes p53 away from endogenous FOXO4, liberated p53 can access its apoptotic target genes, triggering mitochondrial outer membrane permeabilization and caspase activation — selectively killing the senescent cell. Crucially, non-senescent cells do not depend on FOXO4-p53 interaction for survival (they have intact cell cycle regulation and don't upregulate FOXO4), so they are unaffected by FOXO4-DRI. This selectivity — killing only 'zombie' senescent cells while sparing healthy cells — makes FOXO4-DRI a true senolytic agent. In the original 2017 Cell publication by de Keizer et al., FOXO4-DRI treatment in aged mice reduced senescent cell burden and restored physical fitness, fur density, and renal function.
Regulatory Status
Not FDA approved. Preclinical only. Published in Cell (2017) by Erasmus University. No clinical trials yet. Available through specialty research suppliers at high cost.
Risks & Safety
Serious
theoretical risk of killing beneficial senescent cells needed for wound healing and tumor suppression, which could impair tissue repair; no data on effects on the body's cancer surveillance. No human trial data available.
Compare FOXO4-DRI With
Research Papers
8Published: January 14, 2025
AI Summary
Endothelial cell dysfunction during aging is a key driver of vascular aging and related diseases; however, effective strategies to selectively eliminate senescent endothelial cells and restore vascular function remain lacking. FOXO4-DRI, a novel peptide-based intervention, specifically disrupts the interaction between FOXO4 and P53, thereby inducing apoptosis in senescent cells. This study inno...
Published: June 30, 2025
AI Summary
A central process contributing to the phenotype of aging is cellular senescence. We recently identified the FOXO4 - p53 axis as pivotal in maintaining the viability of senescent cells, and that senescent cells can be targeted selectively with the senolytic peptide FOXO4-DRI. Here, we solve the solution NMR structural models of the p53 transactivation domain in complex with the FOXO4 forkhead do...
Published: February 23, 2025
AI Summary
Keloids are pathological scars exhibiting tumour-like aggressiveness and high recurrence rate. Here we find increased proportion of pro-inflammatory and mesenchymal fibroblast subpopulations and senescent fibroblasts, and enhanced expression of senescence-associated secretory phenotype genes using single-cell RNA sequencing analysis, as well as elevated p16 protein and more β-galactosidase-posi...
Published: October 18, 2023
AI Summary
Pulmonary fibrosis (PF) occurs in various end stages of lung disease, and it is characterized by persistent scarring of the lung parenchyma with excessive deposition of extracellular matrix (ECM), leading to degressive quality of life and earlier mortality. FOXO4-D-Retro-Inverso (FOXO4-DRI), a synthesis peptide as a specific FOXO4 blocker, selectively induced dissociation of the FOXO4-p53 compl...
Published: February 20, 2023
AI Summary
Senescent cells (SCs) are involved in proliferative disorders, but their role in pulmonary hypertension remains undefined. We investigated SCs in patients with pulmonary arterial hypertension and the role of SCs in animal pulmonary hypertension models..
Published: June 4, 2022
AI Summary
Pulmonary fibrosis (PF) is a progressive interstitial lung disease with limited treatment options. The incidence and prevalence of PF is increasing with age, cell senescence has been proposed as a pathogenic driver, the clearance of senescent cells could improve lung function in PF. FOXO4-D-Retro-Inverso (FOXO4-DRI), a synthesis peptide, has been reported to selectively kill senescent cells in ...
Published: December 7, 2021
AI Summary
Cancer cell radioresistance is the primary cause of the decreased curability of non-small cell lung cancer (NSCLC) observed in patients receiving definitive radiotherapy (RT). Following RT, a set of microenvironmental stress responses is triggered, including cell senescence. However, cell senescence is often ignored in designing effective strategies to resolve cancer cell radioresistance.
Published: April 28, 2021
AI Summary
Autologous chondrocyte implantation (ACI) is a procedure used to treat articular cartilage injuries and prevent the onset of post-traumatic osteoarthritis. In vitro expansion of chondrocytes, a necessary step in ACI, results in the generation of senescent cells that adversely affect the quality and quantity of newly formed cartilage. Recently, a senolytic peptide, fork head box O transcription ...
Frequently Asked Questions
What is FOXO4-DRI?
A peptide designed to selectively kill 'zombie cells' — old, damaged cells that have stopped dividing but stay alive and pump out inflammatory signals. They accumulate with age and contribute to chronic inflammation. This peptide breaks the mechanism that keeps them alive, allowing them to die off. In aged mice it showed rejuvenating effects, but it's still highly experimental for humans.
What is FOXO4-DRI used for?
A peptide designed to selectively kill 'zombie cells' — old, damaged cells that have stopped dividing but stay alive and pump out inflammatory signals. They accumulate with age and contribute to chronic inflammation. This peptide breaks the mechanism that keeps them alive, allowing them to die off. In aged mice it showed rejuvenating effects, but it's still highly experimental for humans.
What is the dosage for FOXO4-DRI?
Research only: 5-10 mg/kg in mouse studies (intraperitoneal). No established human dosing protocol. Very expensive and extremely limited availability.
What are the side effects of FOXO4-DRI?
Serious: theoretical risk of killing beneficial senescent cells needed for wound healing and tumor suppression, which could impair tissue repair; no data on effects on the body's cancer surveillance. No human trial data available.
How does FOXO4-DRI work?
FOXO4-DRI is a D-retro-inverso (DRI) peptide — a peptide composed entirely of D-amino acids (mirror image of natural L-amino acids) assembled in reverse sequence order. This DRI modification makes the peptide virtually invisible to cellular proteases (which have evolved to cleave L-amino acid peptide bonds), dramatically extending its biological half-life while preserving the spatial orientation of key amino acid side chains needed for target interaction. The target is the FOXO4-p53 protein-protein interaction that keeps senescent cells alive. Cellular senescence is a state of permanent cell cycle arrest triggered by DNA damage, oncogene activation, or telomere shortening. Senescent cells would normally undergo p53-mediated apoptosis (programmed cell death), but they evade this fate through a survival mechanism: the transcription factor FOXO4 is selectively upregulated in senescent cells and physically binds to p53, sequestering it in PML (promyelocytic leukemia) nuclear bodies. This binding prevents p53 from activating its pro-apoptotic transcriptional program (PUMA, BAX, NOXA), keeping the damaged cell alive. FOXO4-DRI competitively disrupts this interaction by mimicking the FOXO4 binding interface for p53 but without the nuclear body-localizing function. When FOXO4-DRI competes p53 away from endogenous FOXO4, liberated p53 can access its apoptotic target genes, triggering mitochondrial outer membrane permeabilization and caspase activation — selectively killing the senescent cell. Crucially, non-senescent cells do not depend on FOXO4-p53 interaction for survival (they have intact cell cycle regulation and don't upregulate FOXO4), so they are unaffected by FOXO4-DRI. This selectivity — killing only 'zombie' senescent cells while sparing healthy cells — makes FOXO4-DRI a true senolytic agent. In the original 2017 Cell publication by de Keizer et al., FOXO4-DRI treatment in aged mice reduced senescent cell burden and restored physical fitness, fur density, and renal function.
How is FOXO4-DRI administered?
FOXO4-DRI is administered via subcutaneous injection (research).
What is the half-life of FOXO4-DRI?
The half-life of FOXO4-DRI is Extended (hours to days; D-amino acid configuration resists protease degradation).
Is FOXO4-DRI legal?
Not FDA approved. Preclinical only. Published in Cell (2017) by Erasmus University. No clinical trials yet. Available through specialty research suppliers at high cost.
Related Peptides
AEDG Peptide
A tetrapeptide (Ala-Glu-Asp-Gly) identical to Epithalon's core active sequence — effectively the same compound. Studied for telomerase activation and pineal gland regulation, promoting melatonin production and potentially slowing cellular aging through telomere maintenance. Part of the Khavinson bioregulator peptide family developed in St. Petersburg.
CJC-1295 (no DAC)
One of the most popular growth hormone peptides, often called Mod GRF 1-29. Instead of injecting growth hormone directly, this tells your pituitary gland to release more of its own GH naturally. This is considered healthier than injecting GH directly because your body keeps its normal feedback systems intact. Usually combined with Ipamorelin for much stronger effects — the two work together better than either alone.
CJC-1295 + Ipamorelin
The most commonly prescribed peptide combination in anti-aging and regenerative medicine. Pairs the GHRH analogue CJC-1295 (Mod GRF 1-29) with the selective ghrelin-mimetic Ipamorelin for synergistic, pulsatile growth hormone release. Exploits two complementary signaling pathways — cAMP (GHRH) and calcium/PLC (ghrelin receptor) — to amplify GH pulses while maintaining minimal side effects.
CJC-1295 with DAC
The long-acting version of CJC-1295. After injection it attaches to a protein in your blood (albumin), which keeps it active for nearly a week instead of just 30 minutes. This means you only need to inject once a week. The trade-off is that it keeps growth hormone elevated constantly rather than in natural pulses, which some practitioners consider less ideal for your body. More convenient but potentially less natural than the no-DAC version.